Miguel García-Pardo

487 total citations
22 papers, 159 citations indexed

About

Miguel García-Pardo is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Miguel García-Pardo has authored 22 papers receiving a total of 159 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 8 papers in Cancer Research. Recurrent topics in Miguel García-Pardo's work include Lung Cancer Treatments and Mutations (15 papers), Cancer Genomics and Diagnostics (7 papers) and Lung Cancer Research Studies (6 papers). Miguel García-Pardo is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Cancer Genomics and Diagnostics (7 papers) and Lung Cancer Research Studies (6 papers). Miguel García-Pardo collaborates with scholars based in Canada, Spain and United States. Miguel García-Pardo's co-authors include Natasha B. Leighl, Maisam Makarem, Janice J.N. Li, Deirdre Kelly, Antonio Calles, Laura Mezquita, Joao V. Alessi, Carlos H. Barrios, Humaid O. Al‐Shamsi and Adrian G. Sacher and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Miguel García-Pardo

17 papers receiving 156 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Miguel García-Pardo Canada 6 86 83 67 63 15 22 159
Chuangzhou Rao China 7 61 0.7× 82 1.0× 55 0.8× 78 1.2× 12 0.8× 23 149
Katrin Heider United Kingdom 6 52 0.6× 101 1.2× 44 0.7× 85 1.3× 18 1.2× 12 155
Rowena Sharpe United Kingdom 3 76 0.9× 71 0.9× 51 0.8× 58 0.9× 7 0.5× 6 137
Zhihong Zhang China 7 73 0.8× 93 1.1× 63 0.9× 61 1.0× 32 2.1× 22 165
Tiana Raveloarivahy France 5 111 1.3× 74 0.9× 59 0.9× 99 1.6× 14 0.9× 9 178
Laia Serrano Spain 7 73 0.8× 64 0.8× 55 0.8× 48 0.8× 10 0.7× 9 156
Clarinda Chua Singapore 7 39 0.5× 75 0.9× 77 1.1× 50 0.8× 43 2.9× 9 160
Masyar Gardizi Germany 5 85 1.0× 38 0.5× 65 1.0× 58 0.9× 12 0.8× 9 124
Paul van der Leest Netherlands 9 110 1.3× 184 2.2× 101 1.5× 71 1.1× 50 3.3× 13 222
Karen Hosking United Kingdom 3 102 1.2× 193 2.3× 70 1.0× 89 1.4× 46 3.1× 5 230

Countries citing papers authored by Miguel García-Pardo

Since Specialization
Citations

This map shows the geographic impact of Miguel García-Pardo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Miguel García-Pardo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Miguel García-Pardo more than expected).

Fields of papers citing papers by Miguel García-Pardo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Miguel García-Pardo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Miguel García-Pardo. The network helps show where Miguel García-Pardo may publish in the future.

Co-authorship network of co-authors of Miguel García-Pardo

This figure shows the co-authorship network connecting the top 25 collaborators of Miguel García-Pardo. A scholar is included among the top collaborators of Miguel García-Pardo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Miguel García-Pardo. Miguel García-Pardo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
García-Pardo, Miguel, et al.. (2025). Carcinoma de pulmón de célula no pequeña. Medicine - Programa de Formación Médica Continuada Acreditado. 14(27). 1580–1594.
2.
3.
Schmid, Sabine, Miguel García-Pardo, Kristen Dietrich, et al.. (2024). Immediate Versus Deferred Systemic Therapy in Patients With Mesothelioma. Clinical Lung Cancer. 25(7). e277–e285.e3.
4.
García-Pardo, Miguel, Joao V. Alessi, Carlos H. Barrios, et al.. (2024). Geographic differences in lung cancer: focus on carcinogens, genetic predisposition, and molecular epidemiology. Therapeutic Advances in Medical Oncology. 16. 12675996–12675996. 15 indexed citations
5.
Schmid, Sabine, Miguel García-Pardo, Sierra Cheng, et al.. (2024). Outcomes with non-small cell lung cancer and brain-only metastasis. Heliyon. 10(17). e37082–e37082.
6.
Garralda, Elena, Andrew G. Gianoukakis, Matthew H. Taylor, et al.. (2024). A phase-1 dose escalation and expansion study of EP0031, a next-generation selective RET inhibitor (SRI), in patients with SRI-naïve or pretreated advanced RET-altered NSCLC and other tumors.. Journal of Clinical Oncology. 42(16_suppl). 8556–8556. 2 indexed citations
7.
Chan, Sze Wah Samuel, M. Catherine Brown, Jae Lee, et al.. (2023). Presentation and outcomes of KRASG12C mutant non-small cell lung cancer patients with stage IV disease at diagnosis (de novo) versus at recurrence. Cancer Treatment and Research Communications. 37. 100774–100774.
8.
9.
García-Pardo, Miguel & Natasha B. Leighl. (2023). “Plasma-first” approach for molecular genotyping in non-small cell lung cancer: A narrative review. SHILAP Revista de lepidopterología. 2. 100123–100123. 1 indexed citations
10.
Schmid, Sabine, Miguel García-Pardo, Sierra Cheng, et al.. (2022). Treatment patterns and outcomes in early-stage ALK-rearranged non-small cell lung cancer. Lung Cancer. 166. 58–62. 7 indexed citations
11.
Patel, Devalben, Catherine Brown, Miguel García-Pardo, et al.. (2022). Abstract 4087: Developing a standardized framework for curating oncology datasets generated by manual abstraction and artificial intelligence. Cancer Research. 82(12_Supplement). 4087–4087. 1 indexed citations
12.
García-Pardo, Miguel, et al.. (2022). Vaccine Therapy in Non-Small Cell Lung Cancer. Vaccines. 10(5). 740–740. 13 indexed citations
13.
Schmid, Sabine, Sierra Cheng, Miguel García-Pardo, et al.. (2022). Real-World Treatment Sequencing, Toxicities, Health Utilities, and Survival Outcomes in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer. Clinical Lung Cancer. 24(1). 40–50. 14 indexed citations
14.
García-Pardo, Miguel, Maisam Makarem, Janice J.N. Li, Deirdre Kelly, & Natasha B. Leighl. (2022). Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges. British Journal of Cancer. 127(4). 592–602. 75 indexed citations
15.
Schmid, Severin, Miguel García-Pardo, Katrina Hueniken, et al.. (2021). FP01.03 Prevalence, Treatment Patterns and Long-Term Clinical Outcomes of Patients with EGFR Positive Resected Stage IB-IIIA NSCLC. Journal of Thoracic Oncology. 16(10). S945–S945. 2 indexed citations
16.
García-Pardo, Miguel, et al.. (2021). Molecular Profiling and Targeted Therapy in Cholangiocarcinoma: An Observational, Retrospective Multicenter Study. Journal of Gastrointestinal Cancer. 52(2). 814–818. 3 indexed citations
17.
García-Pardo, Miguel & Antonio Calles. (2021). ROS-1 NSCLC therapy resistance mechanism. 4. 16–16. 8 indexed citations
18.
Makarem, Maisam, Miguel García-Pardo, & Natasha B. Leighl. (2021). Plasma-Based Genotyping in Advanced Solid Tumors: A Comprehensive Review. Cancers. 13(21). 5299–5299. 4 indexed citations
19.
Stachura, Irene, et al.. (1983). Talwin addict nephropathy.. PubMed. 19(3). 147–53. 5 indexed citations
20.
Sommer, T., et al.. (1981). [Pleural metastases can simulate a mesothelioma].. PubMed. 76(22). 626–9. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chuangzhou Rao Breakdown of academic impact, for papers by Katrin Heider Breakdown of academic impact, for papers by Rowena Sharpe Breakdown of academic impact, for papers by Zhihong Zhang Breakdown of academic impact, for papers by Tiana Raveloarivahy Breakdown of academic impact, for papers by Laia Serrano Breakdown of academic impact, for papers by Clarinda Chua Breakdown of academic impact, for papers by Masyar Gardizi Breakdown of academic impact, for papers by Paul van der Leest Breakdown of academic impact, for papers by Karen Hosking
Rankless by CCL
2026